FOLH1 and prostate carcinoma: In the multidose efficacy study, we showed that 212Pb-ADVC001 has comparable effectiveness in both naïve (group 4) and 177Lu-treated (group 3) prostate cancer tumors, indicating that 212Pb-PSMA therapy may be a potential treatment option for patients who progress after 177Lu-PSMA therapy, though clinical validation is still required.